Key Drivers
- Liquidity Cushion
- Rising Leverage
- Ongoing Losses
AIAI Summary
INBX has shifted from a broad platform story to a binary, catalyst-driven biotech where upside now depends almost entirely on ozekibart regulatory progress and INBRX-106 data, while weak fundamentals, ongoing cash burn, and dilution/leverage risk mean the stock remains a high-risk hold until execution is confirmed.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Cushion
- •Rising Leverage
- •Ongoing Losses
INBX has strong near-term liquidity but poor fundamentals, with rising debt, negative equity, persistent losses, and a tiny revenue base despite a very high valuation.
Price Behavior
Key Price Behavior Insights:
- •Failed rebound
- •Fragile momentum
- •Key support
Over the last month, INBX has been range-bound and volatile, with a failed rebound below $97-$98 and key support now at $83-$84 to watch for trend damage.
Sharp rally from $79.25 to $98.36 quickly reversed back to $88.37
Sentiment & News
Key News Insights:
- •FDA review
- •Pivotal data
- •Phase 3 start
Inhibrx is increasingly a clinical-stage biotech, with ozekibart's FDA review and INBRX-106's upcoming pivotal/Phase 3 milestones driving near-term value.
This update is constructive for the stock as it sharpens the company's value drivers around a clear regulatory catalyst and multiple near-term clinical readouts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings